JR-131 vs NNG-DEPO

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Kidney Disease

Shared mechanism: Erythropoietin receptor (EPO-R) · full Chronic Kidney Disease pipeline

JR-131

Marketed by Kissei Pharmaceutical and partners

Phase 3 in Chronic Kidney Diseasebiologic (darbepoetin alfa biosimilar)
Partial signal

NCT02912494 · Phase 3 · completed

The study was double-blind and used an active darbepoetin alfa comparator, but the registry does not state whether participants were randomized or report the sample size. Its primary endpoint was change in hemoglobin, a surrogate measure. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Reported efficacy

Change from baseline in Hemoglobin level (24 weeks): Change in Hb level from baseline to end of treatment (24 weeks): JR-131 −0.42 ± 0.73 g/dL vs darbepoetin alfa −0.43 ± 0.77 g/dL; between-group difference 0.01 g/dL (95% CI −0.19 to 0.20), within the prespecified equivalence margin of −0.5 to 0.5 g/dL (met)

Result source: NCT02912494

NNG-DEPO · Stimus

Developed by Nanogen Pharmaceutical Biotechnology

Phase 3 in Chronic Kidney Diseasebiologic (registry-typed, subtype undisclosed)
Partial signal

NCT05585645 · Phase 3 · completed

The trial was randomized, double-blind, and actively controlled with Aranesp, enrolling 214 participants. However, its primary endpoint was a hemoglobin change measure rather than a hard clinical outcome, and no primary comparison results are available.

No aligned efficacy figure on record for this race.

Results for Chronic Kidney Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointJR-131NNG-DEPO
Kidney composite outcome—Not posted · NCT02912494—Not posted · NCT05585645
UACR, % change—Not posted · NCT02912494—Not posted · NCT05585645
eGFR slope—Not posted · NCT02912494—Not posted · NCT05585645
Haemoglobin, change—Not posted · NCT02912494—Not posted · NCT05585645

Kidney composite outcome

JR-131
—Not posted · NCT02912494
NNG-DEPO
—Not posted · NCT05585645

UACR, % change

JR-131
—Not posted · NCT02912494
NNG-DEPO
—Not posted · NCT05585645

eGFR slope

JR-131
—Not posted · NCT02912494
NNG-DEPO
—Not posted · NCT05585645

Haemoglobin, change

JR-131
—Not posted · NCT02912494
NNG-DEPO
—Not posted · NCT05585645
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

NNG-DEPO: no structured comparison results are available for Chronic Kidney Disease.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

JR-131
Change in Hb level from baseline to end of treatment (24 weeks): JR-131 −0.42 ± 0.73 g/dL vs darbepoetin alfa −0.43 ± 0.77 g/dL; between-group difference 0.01 g/dL (95% CI −0.19 to 0.20), within the prespecified equivalence margin of −0.5 to 0.5 g/dL NCT02912494 · Phase 3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: JR-131's landscape · NNG-DEPO's landscape